nuere, you've done it again with a good article that gives (albeit faint) hope to long suffering Geron holders. Of interst is on clinicaltrials.gov there is a CLL study that started several years ago (as a phase I/II) study later downgraded to phase I that has never been "completed". When I asked Geron about this they never committed as to why the study had not been up dated as completed. Perhaps this? Perhaps we might see a modification to the current "inactive" protocol" now that would be interesting. I think Geron in the days of Tom Okarma was expecting a dramatic result with CLL and imetelstat. Clearly this did not happen. I believe Sergi left the company which I found disappointing but am pleased to see him publishing from a first class institution where he apparently landed and has pursued the imetelstat story. Are you able to access the whole article and extrapolate whether the doses of imetelstat used in vivo have clinical relevance? One problem is that while the drug seems to "work" the doses required for effect could be problematic. Perhaps in combination with fludarabine lower doses could be used. I have seen NO benchwork to support the current MF trial and the ET trial allegedly was seen as proof of concept but its hard for me to see ET and MF as the "same disease" although clearly clonal precursors seem to have a commonality. Best regards, please keep relevant articles (and commentary) coming. I think Geron has about 50 million left. If good data then dilution or acquisition or partnership, if bad data, company death. Best Regards, bp
